Pfizer Short Term: the downside prevails as long as 26.1 is resistance
Apr 27, 2024 04:10
Pfizer (PFE.US)
-0.4-1.42%
the downside prevails as long as 26.1 is resistance.
Our pivot point stands at 26.1.
Our preference: the downside prevails as long as 26.1 is resistance.
Alternative scenario: the upside breakout of 26.1 would call for 26.9 and 27.4.
Comment: the RSI is below its neutrality area at 50. The MACD is below its signal line and negative. The configuration is negative. Moreover, the share stands below its 20 and 50 day moving average (respectively at 26.28 and 26.9604).
Supports and resistances:
27.4 **
26.9 *
26.1 **
25.8
25.4 (USD-last)
24.3
23.9 **
23.4 *
23 **
Our preference: the downside prevails as long as 26.1 is resistance.
Alternative scenario: the upside breakout of 26.1 would call for 26.9 and 27.4.
Comment: the RSI is below its neutrality area at 50. The MACD is below its signal line and negative. The configuration is negative. Moreover, the share stands below its 20 and 50 day moving average (respectively at 26.28 and 26.9604).
Supports and resistances:
27.4 **
26.9 *
26.1 **
25.8
25.4 (USD-last)
24.3
23.9 **
23.4 *
23 **
Disclaimer: References, analysis and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgment of the analyst, without considering the investment objectives and financial situation of the investors. All strategic opinions do not constitute investment advice or recommendations and are for references only. Our company also does not guarantee the accuracy of the strategic views and does not take any responsibility for the negative results caused by the trading strategies.